Journal of Clinical Trials, Pathology and Case StudiesJournal of Clinical Trials, Pathology and Case StudiesJournal of Clinical Trials, Pathology and Case StudiesJournal of Clinical Trials, Pathology and Case Studies2578-224XOmmega Online PublishersNew Jersey, USA1959Research ArticleLong Term Follow up of Patients with Advanced Cancers after Chemotherapy and Traditional Medicine (82 Cases)Long Term Follow up of Patients with Advanced Cancers after Chemotherapy and Traditional Medicine (82 Cases)George ZhuThe Institute of Oncology Tehran University of Medical Science TehranEditor* E-mail: sansan4240732@163.com
The authors have declared that no competing interests exist.
20182509201831JCPC-18-RA-195904092018200920182018Creative Commons Attribution LicenseThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. nbsp Traditional systems of medicine all over the world even traditional medicine and cancer have been using plants and plants products for therapeutic intention The purpose of these retrospective trials is to evaluate the clinical efficacy of chemotherapy in conjunction with traditional medicine TCM for a broad variety of cancers Methods 82 patients with available cancers were concluded in the study during September 1993 - May 2018 The sex ratio of male female was 55 27 respectively The mean age at onset was 46 4 years range 10 - 79 years All patients were treated with different dosage of various chemotherapy in combination with TCM or traditional medicine alone The basic chemotherapeutic regimen consisted of vincristine VCR 1 - 2 mg week cyclophosphamide CTX 200 - 1 000 mg week mitomycin C MMC 2 - 4 mg week and 5-fluorouracil 5-FU 250 - 500 mg day In addition according to patient condition the additional drug doxorubicin ADM 20 mg week in lymphoma and metastatic breast cancer demethylcantharidin in liver cancer and cisplatin DDP or interleukin-2 PHA or gefitinib in lung cancer The detail prescription of TCM varied among a broad variety of carcinomas see full text case reports The criteria of complete remission CR and or partial remission PR is according to the rules where physicians have in common with in clinics Results In 82 cases the CR was obtained in 37 45 1 advanced cancers a short CR in 13 15 9 cases PR in 26 31 7 cancers Stable disease in 6 cases In differential types of 20 patients over ten years lymphoma occupied 8 cases 40 As to approach to the schedule of drug administration 11 lymphoma obtained CR via CVP or COMF COMA CTX VCR MMC ADM regimen and TCM or antibiotics and immunotherapy Five advanced gastric cancer were successfully treated using MFC and cinobufacini cantharidin and TCM In follow up one HCC accompanied with colon polyps obtained CR via hepatectomy and targeting oncogenic receptor tyrosine kinase inhibitor sorafenib Among two lung cancers one female with metastatic lung cancer was given targeting oncogenic receptor EGFR gefitinib therapy after the combination chemotherapy which was stable disease for 8 months CR can also be achieved in one advanced cholangiocarcinoma and one advanced gallbladder cancer through major protocol of TCM and the addition of small dosage of chemotherapy Two patients the breast has inflamed redness swelling and an enlarged and firm mass palpable Cures were obtained through the primary use of traditional medicine with antibiotics regimen Traditional herbs consisted of taraxacum honeysuckle asparagus cremastra appendiculata coix lacryma cordate houttuynia scutellaria barbate d don and oldenlandia diffusa roxb Among those long-term survivors 34 carcinomas obtained in disease-free survival over 5years 22 cancers were survival over 10 years the longest four patients over 25 years Conclusion In this study I experienced that a CR was a pivotal influencing factor in those longest survival patients and traditional medicine was also recommended Down regulating oncogenic receptors may be useful paradigm and perspective in currently the third line setting of clinical target therapy and in rendering our better understanding of cancer biology 10